AbCellera Biologics Inc. recently held its second-quarter 2026 earnings call, where the company highlighted a significant strategic pivot towards internal drug development and the enhancement of its multispecific T-cell engager (TCE) platform. Management detailed the successful completion of Phase 2 enrollment for their lead program, ABCL635, alongside the announcement of new collaborative partnerships with industry giants Jazz Pharmaceuticals and Vertex Pharmaceuticals. The company also assured stakeholders of its robust financial health, with sufficient liquidity to sustain operations and pipeline investments for at least three years. The discussion underscored a clear commitment to advancing their clinical pipeline while concurrently leveraging their established discovery capabilities for high-value external collaborations.
During the call, Carl L. Hansen, the company's President and CEO, provided an in-depth look at the progress of ABCL635, a promising treatment for moderate to severe hot flashes associated with menopause. Enrollment and initial dosing for the Phase 2 trial were completed ahead of schedule in June, with top-line data anticipated in August 2026. Hansen expressed optimism, noting that positive data would significantly de-risk the program, paving the way for late-stage clinical development and exploring its application in cancer treatment-related vasomotor symptoms (VMS). The company aims for ABCL635 to demonstrate a clean safety profile and efficacy comparable to existing small molecule treatments, specifically targeting at least a 20% response rate relative to placebo and a reduction of at least two hot flashes per day.
Furthermore, AbCellera's T-cell engager platform emerged as a central theme, celebrating five years of intensive investment and development. This platform now boasts a comprehensive suite of binders, technologies, and biological insights crucial for generating optimal TCEs. Hansen emphasized that this advanced toolkit positions AbCellera competitively for both internal programs and strategic partnerships. The recent collaborations with Vertex and Jazz Pharmaceuticals exemplify this strategy, bringing over $110 million in upfront payments and potential downstream payments exceeding $4 billion. The Jazz Pharmaceuticals deal, in particular, was lauded as one of the largest TCE discovery deals reported to date, encompassing three confirmed discovery programs and options for two additional ones.
Andrew Booth, AbCellera's Chief Financial Officer, reiterated the company's strong financial standing, reporting over $565 million in cash and equivalents, supplemented by approximately $110 million in committed government funding. Despite a decrease in Q2 2026 revenue to $4.1 million from $17.1 million in Q2 2025, largely due to a shift towards internal programs, the company maintained a solid liquidity position. Research and development expenses increased to $46 million, reflecting heightened investment in internal pipeline initiatives, while sales, general, and administrative expenses decreased following the resolution of intellectual property litigation. The company recorded a net loss of $55.4 million for the quarter, or $0.18 per share. Looking ahead, the company's treasury management includes $420 million invested in short-term marketable securities, and management projects existing liquidity to support pipeline investments for at least three years, ensuring sustained growth and innovation.
\